Currently, there are 472.70M common shares owned by the public and among those 467.65M shares have been available to trade.
The company’s stock has a 5-day price change of -2.14% and -2.63% over the past three months. DKNG shares are trading 9.05% year to date (YTD), with the 12-month market performance up to 25.05% higher. It has a 12-month low price of $25.73 and touched a high of $49.57 over the same period. DKNG has an average intraday trading volume of 9.00 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.11%, 6.69%, and -2.19% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of DraftKings Inc. (NASDAQ: DKNG) shares accounts for 72.19% of the company’s 472.70M shares outstanding.
It has a market capitalization of $18.66B and a beta (3y monthly) value of 1.81. The earnings-per-share (ttm) stands at -$0.87. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.30% over the week and 3.31% over the month.
Earnings per share for the fiscal year are expected to increase by 84.03%, and 361.31% over the next financial year.
Looking at the support for the DKNG, a number of firms have released research notes about the stock. Susquehanna stated their Positive rating for the stock in a research note on October 07, 2024, with the firm’s price target at $48-$50. Exane BNP Paribas coverage for the DraftKings Inc. (DKNG) stock in a research note released on September 10, 2024 offered a Neutral rating with a price target of $35. UBS was of a view on September 04, 2024 that the stock is Buy, while Susquehanna gave the stock Positive rating on September 04, 2024, issuing a price target of $47- $48. Oppenheimer on their part issued Outperform rating on July 01, 2024.
